Fate Therapeutics, Inc. ( FATE) - Key Metrics
FATE Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.02 | -$0.25 | -$0.19 | -$0.20 |
| 2026Q1 | $0.01 | -$0.26 | -$0.26 | -$0.26 |
| 2025Q4 | $0.01 | -$0.27 | -$0.20 | -$0.21 |
| 2025Q3 | $0.01 | -$0.27 | -$0.20 | -$0.22 |
| 2025Q2 | $0.02 | -$0.29 | -$0.21 | -$0.22 |
FATE Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -2.70 |
| 2026Q1 | 0% | -1.15 |
| 2025Q4 | 0% | -0.91 |
| 2025Q3 | 0% | -1.17 |
| 2025Q2 | 0% | -0.97 |
FATE
Price: $1.79
52 week price:
Earnings Per Share: -1.09 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.6 million
Ebitda: -10.1 millionMarket Capitalization: 278.0 million